TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00953121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and CPT-11 and Carboplatin
Description: Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and CPT-11 and Carboplatin
Description: Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and CPT-11 and Carboplatin
Description: Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
Study: NCT00970294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion Program
Description: 10 week health promotion program 3-4 times per week
Study: NCT03290300

Intervention type: DEVICE
Intervention: Vivaer Stylus
Description: Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
Study: NCT02994147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-only control study medication is the same formulation as active treatment without active ingredient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201CR
Description: The investigational product is formulated as controlled-release (CR) tablets
Study: NCT00887419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Description: Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
Study: NCT03431961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: 220 mcg administered twice daily for 14 days
Study: NCT04360252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gracie Diet
Description: The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet.~The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest.
Study: NCT04198181

Intervention type: PROCEDURE
Intervention: Surgery
Description: Resective surgery included lobectomy (partial or total brain lobe resection), tuberectomy (epileptogenic tuber resection), and tuberectomy plus (resection of epileptogenic tuber and perituberal gyri). Tuberectomy was typically performed on the epileptogenic tuber within or near an eloquent area. Lobectomy was performed in patients with large epileptogenic tubers in the brain lobes. Multiple lobectomies, tuberectomies, tuberectomies plus, and lobectomy combined with tuberectomy/tuberectomies plus were further performed in patients with multiple epileptogenic tubers.
Study: NCT04472104

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBCT-S
Description: Group mindfulness treatment for sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SexEd
Description: Group sex education on sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
Study: NCT00745316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonapofylline
Description: Oral Tonapofylline - 2 capsules bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonapofylline
Description: Oral Tonapofylline - 2 capsules bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonapofylline
Description: Oral Tonapofylline - 2 capsules bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonapofylline
Description: Oral Tonapofylline - 2 capsules bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonapofylline
Description: Oral Tonapofylline - 2 capsules bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo - 2 capsules bid
Study: NCT04372329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP4HealthySleep system
Description: Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP4HealthySleep system
Description: Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy
Study: NCT02397720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04668300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT02397720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04668300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Given IV
Study: NCT02453282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)+Tremelimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Carboplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Cisplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Carboplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + Cisplatin
Description: Chemotherapy Agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + Carboplatin
Description: Chemotherapy Agents

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study: NCT02322775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered subcutaneously every 4 weeks
Study: NCT00923013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
Study: NCT00870025

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: 200 IU, sc, every 5 days, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: diluent, every 5 days, s.c., 4 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: diluent, every 5 days, s.c., 4 doses
Study: NCT02431728

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 5 mg capsule p.o. at bedtime daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: 5 mg capsule p.o. at bedtime daily
Study: NCT05105009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: * Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~* Oral creatinine load using 5 grams of creatinine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatinine Powder
Description: 5g of creatinine (Sigma) in 250 ml of water was taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 ml iohexol (Omnipaque) intravenously
Study: NCT03524274

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study: NCT00255567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Stibogluconate
Description: Sodium Stibogluconate 20mg/kg/day for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin sulphate
Description: Paromomycin sulphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSG and Paromomycin sulphate
Description: SSG and Paromomycin Sulphate 17 days
Study: NCT03881540

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDNA-MI group
Description: tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements and motivational interviewing counseling. .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDNA-CC group
Description: tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements+ 150 min/week of moderate intensity exercise + and conventional counselling.

Intervention type: OTHER
Group type: OTHER
Intervention: UC group
Description: Meal plan of 1200-1500 kcal/day using conventional foods + 150 min/week of moderate intensity exercise + and conventional counselling
Study: NCT04148430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100mg subcutaneous
Study: NCT04019561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 high dose
Description: MEDI0382 high dose administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEDI0382 high dose
Description: Placebo for MEDI0382 high dose administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 low dose
Description: MEDI0382 low dose administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEDI0382 low dose
Description: Placebo for MEDI0382 low dose administered subcutaneously
Study: NCT03116529

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Radiation, Immunotherapy, Surgery
Description: Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as \>10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease.
Study: NCT04610866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Investigational drug mitapivat (also known as AG-348, AGI-1480 and AGX-0841) is an orally bioavailable, broad-spectrum allosteric activator of alleles of the RBC-specific form of pyruvate kinase (PKR), as well as liver-type pyruvate kinase (PKL) and muscle pyruvate kinase (PKM1 and PKM2).
Study: NCT02974647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT00717470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf®
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf®
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf®
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf®
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral
Study: NCT02974647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT03824158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated advance care planning (in-person or telephonic)
Description: The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based advance care planning
Description: Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
Study: NCT01503086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies
Study: NCT00717470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral
Study: NCT01503086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive Training
Description: Receive computer-assisted cognitive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive Training
Description: Receive computer-assisted cognitive training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00717470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone / prednisone
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone / prednisone
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone / prednisone
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone / prednisone
Description: oral
Study: NCT01503086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04156906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D+ RH genotype matched red cell units for transfusion
Description: Chronically transfused patients with SCD and anti-D will receive D+ RH genotyped matched red cell units for transfusion in addition to standard C, E, and K antigen matching and being hemoglobin S negative, which is the Children's Hospital of Philadelphia institutional standard of care for patients with SCD. RH genotyping of donor units will be performed by the New York Blood Center (NYBC) Immunogenetics laboratory.
Study: NCT03431961

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 14 days
Study: NCT01087502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1-4 mg daily after 12 weeks
Study: NCT04426669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TIL)
Description: Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TIL)
Description: Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
Study: NCT04194437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Liver System
Description: The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.